Difference between revisions of "Template:Ionotropic glutamate receptor modulators"
Jump to navigation
Jump to search
imported>Medgirl131 |
imported>Medgirl131 |
||
| Line 155: | Line 155: | ||
* [[Neboglamine|Neboglamine (nebostinel)]] | * [[Neboglamine|Neboglamine (nebostinel)]] | ||
* [[Rapastinel|Rapastinel (GLYX-13)]] | * [[Rapastinel|Rapastinel (GLYX-13)]] | ||
| − | * [[Sarcosine]]; ''Polyamine site agonists:'' [[Spermidine]] | + | * [[Sarcosine]]; ''Polyamine site agonists:'' [[Neomycin]] |
| + | * [[Spermidine]] | ||
* [[Spermine]]; ''Other positive allosteric modulators:'' [[24S-Hydroxycholesterol|24''S''-Hydroxycholesterol]] | * [[Spermine]]; ''Other positive allosteric modulators:'' [[24S-Hydroxycholesterol|24''S''-Hydroxycholesterol]] | ||
* {{abbrlink|DHEA|Dehydroepiandrosterone}} ([[prasterone]]) | * {{abbrlink|DHEA|Dehydroepiandrosterone}} ([[prasterone]]) | ||
| Line 184: | Line 185: | ||
* [[cis-1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid|PPDA]] | * [[cis-1-(phenanthrene-2-carbonyl)piperazine-2,3-dicarboxylic acid|PPDA]] | ||
* [[SDZ-220581]] | * [[SDZ-220581]] | ||
| − | * [[Selfotel]]; '' | + | * [[Selfotel]]; ''Glycine site antagonists:'' [[4-Chlorokynurenine|4-Cl-KYN (AV-101)]] |
| − | * [[ | + | * [[5,7-Dichlorokynurenic acid|5,7-DCKA]] |
| − | * [[ | + | * [[7-Chlorokynurenate|7-CKA]] |
| − | * [[ | + | * [[1-Aminocyclopropane-1-carboxylic acid|ACC]] |
| − | * [[ | + | * [[ACEA-1011]] |
| − | * [[ | + | * [[ACEA-1328]] |
| − | * [[ | + | * [[AV-101]] |
| − | * [[MDL- | + | * [[Carisoprodol]] |
| − | * [[ | + | * [[CGP-39653]] |
| − | * [[ | + | * [[CNQX]] |
| + | * [[DNQX]] | ||
| + | * [[Felbamate]] | ||
| + | * [[Gavestinel]] | ||
| + | * [[GV-196771]] | ||
| + | * [[Harkoseride]] | ||
| + | * [[Kynurenic acid]] | ||
| + | * [[Kynurenine]]<!--As a prodrug of kynurenic acid--> | ||
| + | * [[L-689560]] | ||
| + | * [[L-701324]] | ||
| + | * [[Licostinel|Licostinel (ACEA-1021)]] | ||
| + | * [[LU-73068]] | ||
| + | * [[MDL-105519]] | ||
| + | * [[Meprobamate]] | ||
| + | * [[MRZ 2/576]] | ||
| + | * [[PNQX]] | ||
| + | * [[ZD-9379]]; ''Polyamine site antagonists:'' [[Arcaine]] | ||
| + | * [[Co 101676]] | ||
| + | * [[1,3-Diaminopropane|Diaminopropane]] | ||
| + | * [[Diethylenetriamine]] | ||
| + | * [[Huperzine A]] | ||
| + | * [[Putrescine]]; ''Uncompetitive pore blockers (mostly dizocilpine site):'' [[2-MDP]] | ||
* [[3-HO-PCP]] | * [[3-HO-PCP]] | ||
* [[3-MeO-PCE]] | * [[3-MeO-PCE]] | ||
| Line 215: | Line 237: | ||
* [[Dexoxadrol]] | * [[Dexoxadrol]] | ||
* [[Dextrallorphan]] | * [[Dextrallorphan]] | ||
| + | * [[Dextromethorphan]] | ||
| + | * [[Dextrorphan]] | ||
* [[Dieticyclidine]] | * [[Dieticyclidine]] | ||
* [[Diphenidine]] | * [[Diphenidine]] | ||
| Line 230: | Line 254: | ||
* [[Ketobemidone]] | * [[Ketobemidone]] | ||
* [[Lanicemine]] | * [[Lanicemine]] | ||
| + | * [[Levomethadone]] | ||
* [[Loperamide]] | * [[Loperamide]] | ||
* [[Memantine]] | * [[Memantine]] | ||
| − | * [[Methadone]] | + | * [[Methadone]] |
| − | * [[Methorphan | + | * [[Methorphan]] |
| − | * [[Levomethorphan]] | + | * [[Levomethorphan]] |
* [[Methoxetamine]] | * [[Methoxetamine]] | ||
* [[Methoxphenidine]] | * [[Methoxphenidine]] | ||
* [[Milnacipran]] | * [[Milnacipran]] | ||
| − | * [[Morphanol | + | * [[Morphanol]] |
| − | * [[Levorphanol]] | + | * [[Levorphanol]] |
* [[NEFA (drug)|NEFA]] | * [[NEFA (drug)|NEFA]] | ||
* [[Nefopam]] | * [[Nefopam]] | ||
* [[Neramexane]] | * [[Neramexane]] | ||
* [[Nitromemantine]] | * [[Nitromemantine]] | ||
| − | |||
* [[Noribogaine]] | * [[Noribogaine]] | ||
* [[Norketamine]] | * [[Norketamine]] | ||
| Line 262: | Line 286: | ||
* [[Tenocyclidine]] | * [[Tenocyclidine]] | ||
* [[Tiletamine]] | * [[Tiletamine]] | ||
| − | * [[Tramadol | + | * [[Tramadol]]; ''Ifenprodil (NR2B) site antagonists:'' |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
* [[Besonprodil]] | * [[Besonprodil]] | ||
| + | * [[Buphenine|Buphenine (nylidrin)]] | ||
* [[CO-101244|CO-101244 (PD-174494)]] | * [[CO-101244|CO-101244 (PD-174494)]] | ||
* [[Eliprodil]] | * [[Eliprodil]] | ||
* [[Haloperidol]] | * [[Haloperidol]] | ||
| − | * [[Radiprodil]] | + | * [[Isoxsuprine]] |
| + | * [[Radiprodil|Radiprodil (RGH-896)]] | ||
| + | * [[Rislenemdaz|Rislenemdaz (CERC-301, MK-0657)]] | ||
| + | * [[Ro 8-4304]] | ||
* [[Ro 25-6981]] | * [[Ro 25-6981]] | ||
* [[Safaprodil]] | * [[Safaprodil]] | ||
| − | * [[Traxoprodil]]; '' | + | * [[Traxoprodil|Traxoprodil (CP-101606)]]; ''NR2A-selective antagonists:'' [[MPX-004]] |
| − | * [[ | + | * [[MPX-007]] |
| − | * [[ | + | * [[TCN-201]] |
| − | * [[ | + | * [[TCN-213]]; ''Cations:'' [[Hydrogen]] |
| − | + | * [[Magnesium]] | |
| − | + | * [[Zinc]]; ''Alcohols/volatile anesthetics/related:'' [[Benzene]] | |
| − | + | * [[Butane]] | |
| − | * [[ | ||
| − | * [[ | ||
| − | |||
* [[Chloroform]] | * [[Chloroform]] | ||
* [[Cyclopropane]] | * [[Cyclopropane]] | ||
| − | * [[ | + | * [[Desflurane]] |
* [[Diethyl ether]] | * [[Diethyl ether]] | ||
* [[Enflurane]] | * [[Enflurane]] | ||
* [[Ethanol]] | * [[Ethanol]] | ||
| + | * [[Halothane]] | ||
| + | * [[Hexanol]] | ||
| + | * [[Isoflurane]] | ||
| + | * [[Methoxyflurane]] | ||
| + | * [[Nitrous oxide]] | ||
| + | * [[Octanol]] | ||
| + | * [[Sevoflurane]] | ||
| + | * [[Toluene]] | ||
| + | * [[1,1,1-Trichloroethane|Trichloroethane]] | ||
| + | * [[2,2,2-Trichloroethanol|Trichloroethanol]] | ||
| + | * [[Trichloroethylene]] | ||
| + | * [[Ethyl carbamate|Urethane]] | ||
| + | * [[Xenon]] | ||
| + | * [[Xylene]]; ''Unknown/unsorted antagonists:'' [[ARR-15896]] | ||
| + | * [[Bumetanide]] | ||
| + | * [[Caroverine]] | ||
| + | * [[D-α-Aminoadipate|<small>D</small>-αAA]] | ||
| + | * [[Dexanabinol]] | ||
* [[Flufenamic acid]] | * [[Flufenamic acid]] | ||
* [[Flupirtine]] | * [[Flupirtine]] | ||
| + | * [[FPL-12495]] | ||
| + | * [[FR-115427]] | ||
* [[Furosemide]] | * [[Furosemide]] | ||
| − | * [[ | + | * [[Hodgkinsine]] |
* [[Ipenoxazone|Ipenoxazone (MLV-6976)]] | * [[Ipenoxazone|Ipenoxazone (MLV-6976)]] | ||
| − | * [[ | + | * [[MDL-27266]] |
* [[Metaphit]]<!--Irreversible--> | * [[Metaphit]]<!--Irreversible--> | ||
| − | |||
* [[Niflumic acid]] | * [[Niflumic acid]] | ||
| + | * [[Pentamidine]] | ||
* [[Pentamidine isethionate]] | * [[Pentamidine isethionate]] | ||
* [[Piretanide]] | * [[Piretanide]] | ||
| − | * [[ | + | * [[Psychotridine]] |
* [[Transcrocetin]] ([[saffron]]) | * [[Transcrocetin]] ([[saffron]]) | ||
| − | |||
| − | |||
| − | |||
| − | |||
| below = '''''See also:''' [[Template:Receptor modulators|Receptor/signaling modulators]] • [[Template:Metabotropic glutamate receptor modulators|Metabotropic glutamate receptor modulators]] • [[Template:Glutamate metabolism and transport modulators|Glutamate metabolism/transport modulators]]'' | | below = '''''See also:''' [[Template:Receptor modulators|Receptor/signaling modulators]] • [[Template:Metabotropic glutamate receptor modulators|Metabotropic glutamate receptor modulators]] • [[Template:Glutamate metabolism and transport modulators|Glutamate metabolism/transport modulators]]'' | ||
Revision as of 00:35, 3 September 2017
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Ionotropic glutamate receptor modulators|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Ionotropic glutamate receptor modulators|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Ionotropic glutamate receptor modulators|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.